SAREPTA THERAPEUTICS INC. - COMMON STOCK

Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

03 May 2021 07:50:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Apr 2021 17:45:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy

30 Apr 2021 15:05:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Announce First Quarter 2021 Financial Results and Recent Corporate Developments on May 5, 2021

28 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

Sarepta Recommends Stockholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation

26 Apr 2021 15:05:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program

23 Mar 2021 07:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration

18 Mar 2021 15:31:49 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference

15 Mar 2021 07:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments

01 Mar 2021 15:05:01 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

26 Feb 2021 18:12:41 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45

25 Feb 2021 13:10:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Present at Upcoming Investor Conferences

24 Feb 2021 15:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments on March 1, 2021

22 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition

04 Feb 2021 15:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

29 Jan 2021 19:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics

13 Jan 2021 07:30:01 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

08 Jan 2021 07:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

07 Jan 2021 15:05:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Dec 2020 17:30:00 By Nasdaq GlobeNewswire